U.S. markets closed
  • S&P 500

    -40.76 (-0.91%)
  • Dow 30

    -166.42 (-0.48%)
  • Nasdaq

    -137.93 (-0.91%)
  • Russell 2000

    +3.96 (+0.18%)
  • Crude Oil

    -0.01 (-0.01%)
  • Gold

    +2.50 (+0.14%)
  • Silver

    +0.02 (+0.10%)

    -0.0037 (-0.32%)
  • 10-Yr Bond

    +0.0390 (+2.93%)

    -0.0063 (-0.45%)

    +0.2020 (+0.18%)

    -494.89 (-1.03%)
  • CMC Crypto 200

    -32.05 (-2.61%)
  • FTSE 100

    -63.84 (-0.91%)
  • Nikkei 225

    +176.75 (+0.58%)

Gentherm Medical’s Hemotherm® Model 400CE Cardiovascular Heater/Cooler Device Now Able to be Utilized for Treatment of COVID-19 Patients Under U.S. Food and Drug Administration Emergency Use Authorization for ECMO Devices

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NORTHVILLE, Mich., May 28, 2020 (GLOBE NEWSWIRE) -- Gentherm (THRM), a global market leader and developer of innovative thermal management technologies today announced that via the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA), the Company’s Hemotherm® Model 400CE Dual Reservoir Cooler-Heater can be used to treat patients with COVID-19.

The Hemotherm® Model 400CE Dual Reservoir Cooler-Heater delivers reliable, effective blood temperature management control during cardiopulmonary by-pass and other related cardiovascular procedures. In treating COVID-19 patients, the system controls the temperature of the water flowing through a blood oxygenator/heat exchanger that is used to cool or warm blood during long-term respiratory/cardiopulmonary support in an extracorporeal membrane oxygenator (ECMO) circuit.

“The use of the Emergency Use Authorization from the FDA opens the way for Gentherm to provide support to healthcare professionals in treating patients with severe symptoms of COVID-19,” said Phil Eyler, President and CEO of Gentherm. “Thanks to the enormous effort of our team we are able to meet the needs of patients, their families and healthcare workers with a greater sense of urgency and responsibility during this pandemic.”

The use in ECMO therapy is temporary where the EUA allows for the distribution and emergency use of Hemotherm® Model 400CE Dual Reservoir Cooler-Heater only for the treatment of COVID-19.

Gentherm Medical’s Blanketrol® III hyper-hypothermia system is also being used by hospitals across the United States and Europe to support patient temperature management needs during these unprecedented times.

Investor Contact
Yijing Brentano, Gentherm

Media Contacts
Melissa Fischer, Gentherm

About Gentherm
Gentherm (THRM) is a global developer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery thermal management systems, cable systems and other electronic devices. Medical products include patient temperature management systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Gentherm has over 11,000 employees in facilities in the United States, Germany, Canada, China, Hungary, Japan, South Korea, North Macedonia, Malta, Mexico, United Kingdom, Ukraine, and Vietnam. For more information, go to www.gentherm.com.